Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Rhea-AI Summary
Stryker (NYSE:SYK) signed a definitive agreement on April 13, 2026 to acquire Amplitude Vascular Systems to add a next-generation intravascular lithotripsy (IVL) platform for treating calcified peripheral arterial disease.
The technology uses pulsed CO2-generated pressure waves via an IVL balloon catheter, aims to improve deliverability and treatment speed, and will complement Stryker's Peripheral Vascular portfolio once cleared for use. Transaction remains subject to customary closing conditions; both companies will operate separately until close.
Positive
- Signed definitive acquisition agreement on April 13, 2026
- Adds a next-generation IVL platform for calcified peripheral arterial disease
- Expands Peripheral Vascular portfolio to complement existing revascularization offerings
Negative
- Product requires market clearance before commercial deployment
- Transaction is subject to customary closing conditions, so outcome is not guaranteed
- No purchase price disclosed, limiting near-term financial transparency
News Market Reaction – SYK
In the Apr 13 session, SYK gained 2.39%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Asset divestiture | Neutral | +5.0% | VB Spine acquired Stryker’s Cestas spine implant manufacturing facility. |
| Feb 19 | Acquisition completion | Positive | +0.8% | Completion of Inari Medical acquisition and integration into Stryker portfolio. |
| Jan 06 | Large acquisition deal | Positive | -1.7% | Definitive agreement to acquire Inari Medical for about $4.9B in cash. |
| Sep 20 | Neuro acquisition | Positive | -0.1% | Completion of NICO acquisition to expand minimally invasive neuro solutions. |
| Aug 22 | Pain management deal | Positive | +1.6% | Definitive agreement to acquire Vertos Medical for lumbar spinal stenosis treatments. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Acquisition-related headlines have produced mostly modest moves, with both positive and negative reactions, suggesting investor responses depend on deal specifics.
Over the past year, Stryker has used acquisitions and divestitures to refine its portfolio. Deals such as Vertos Medical (Aug 22, 2024), NICO (Sep 20, 2024), and Inari Medical announcements and completion in early 2025 focused on neuro and peripheral vascular growth. A facility sale to VB Spine on Jan 6, 2026 reflected portfolio reshaping. Today’s AVS agreement fits this ongoing M&A-driven expansion in peripheral vascular care.
Key Terms
intravascular lithotripsy medical
peripheral arterial disease medical
revascularization medical
ivl balloon catheter medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease.
The acquisition will strengthen Stryker’s Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker’s existing PV offerings and support the company’s strategy to expand its presence in arterial disease treatment.
“This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” said Kevin Lobo, Chair and CEO, Stryker. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.”
AVS’ technology is designed to use pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter, to fracture calcium and optimize luminal gain. The platform is designed to enhance catheter deliverability, treatment speed and therapy efficiency.
IVL is a fast-growing technology in cardiovascular intervention and is used to treat calcified peripheral and coronary lesions. It is expected to experience strong growth as physicians adopt IVL-based calcium modification in complex procedures.
This transaction is subject to customary closing conditions. Stryker and AVS will continue to operate as separate entities and proceed with business as usual until the transaction closes.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
About Amplitude Vascular Systems (AVS)
Amplitude Vascular Systems (AVS) is a medical device company based in Boston, Mass., focused on treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. It was founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. More information is available at www.avspulse.com.
Contacts
For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com
